Core Viewpoint - The announcement details the share reduction plan executed by major shareholders of Aorite Pharmaceutical Co., Ltd., highlighting the completion of the reduction and the current shareholding status of the involved parties [1][4]. Group 1: Major Shareholder Holding Situation - Before the reduction plan, Aorite Pharmaceutical had a total of 406,195,234 shares, with Tian Tai Boen Investment Management Partnership holding 167,919,800 shares, accounting for 41.34% of the total shares. Tian Tai Boen held 6,606,000 shares (1.63%), Zhejiang Tongben held 153,583,200 shares (37.81%), and Tian Tai Bolong held 7,730,600 shares (1.90%) [2]. Group 2: Implementation Results of the Reduction Plan - On November 5, 2025, the company disclosed the share reduction plan, where Tian Tai Boen, as an employee stock ownership platform, planned to reduce up to 1,000,000 shares (0.25% of total shares) through centralized bidding and block trading within three months, excluding the window period [3]. - As of the announcement date, Tian Tai Boen successfully reduced 1,000,000 shares (0.25% of total shares), completing the reduction plan. Tian Tai Boen currently holds 5,606,000 shares (1.38%) [4].

Group 1 - The core point of the article is that Aorite (SH 605116) announced a share reduction by Tian Tai Bo En, which has completed a plan to sell 1,000,000 shares, representing 0.25% of the company's total share capital [1] - As of the announcement date, Tian Tai Bo En still holds 5,606,000 shares, which is 1.38% of the total share capital of Aorite [1] - Aorite's revenue composition for the first half of 2025 is as follows: 85.12% from self-produced raw materials and intermediates, 11.64% from formulations, 2.74% from trading, and 0.5% from other businesses [1] Group 2 - The current market capitalization of Aorite is 9.7 billion yuan [1]

格隆汇12月24日丨奥锐特(605116.SH)公布，截至本公告披露日，天台铂恩以集中竞价交易方式减持100 万股，占公司总股本的0.25%，本次减持计划已实施完毕。天台铂融恩目前仍持有公司股份560.6万股， 占公司总股本的1.38%。 ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-088 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 股东减持股份结果公告 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，奥锐特药业股份有限公司（以下简称"公司"）的股 份总数为 406,195,234 股，天台铂恩投资管理合伙企业（有限合伙）（以下简称 "天台铂恩"）及其一致行动人浙江桐本投资有限公司（以下简称"浙江桐本"）、 天台铂融投资合伙企业（有限合伙）（以下简称"天台铂融"）合计持有公司股份 167,919,800 股，占公司总股本的 41.34%。其中天台铂恩持有公司股份 6,606,000 股，占公司总股本的 1.63%；浙江桐本持有公司股份 153,583,200 股，占公司总 股本的 37.81%；天台铂融持有公司股份 7,730,600 股，占公司总股本的 1.90%。 上述股份均来源 ...

Group 1 - The core viewpoint of the news is that Aorite Pharmaceutical Co., Ltd. has seen a stock price increase of 5.04%, reaching 23.15 CNY per share, with a total market capitalization of 9.403 billion CNY [1] - Aorite Pharmaceutical, established on March 5, 1998, and listed on September 21, 2020, specializes in the research, production, and sales of specialty APIs and pharmaceutical intermediates [1] - The company's revenue composition includes 85.12% from API and intermediate sales, 11.64% from finished drug sales, 2.74% from import and export trade, and 0.50% from other sources [1] Group 2 - From the perspective of fund holdings, Aorite is a major holding in the China Life Asset Management's fund, specifically the China Life Asset Health Science Mixed A Fund (005043), which holds 210,000 shares, unchanged from the previous period [2] - The fund's net asset value proportion for Aorite is 9.07%, making it the largest holding in the fund [2] - The fund has experienced a loss of 3.61% this year, ranking 7991 out of 8088 in its category, and a loss of 4.86% over the past year, ranking 7960 out of 8057 [2]

Group 1 - The company, Aorite Pharmaceutical Co., Ltd., has received a GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, confirming that its production lines meet the required standards [1] - The inspection covered the production of active pharmaceutical ingredients, specifically mometasone furoate and betamethasone, conducted from November 12 to November 14, 2025 [1] - The inspection concluded that the company complies with the relevant laws and regulations, including the Drug Administration Law and the Good Manufacturing Practice (GMP) guidelines [1] Group 2 - The company is expected to maintain stable product quality and production capacity, which will help meet market demand for its pharmaceutical products [3] - The company acknowledges that future sales may be influenced by market conditions and industry policies, indicating potential uncertainties in the pharmaceutical sector [3]

| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-087 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 奥锐特药业股份有限公司 关于通过药品 GMP 符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，奥锐特药业股份有限公司（以下简称"奥锐特"或"公司"）收到浙 江省药品监督管理局签发的《药品GMP符合性检查告知书》（浙2025第0267号、浙 2025第0268号），现将相关情况公告如下： 一、GMP 检查相关信息 企业名称：奥锐特药业股份有限公司 生产地址：浙江省天台县八都工业园区 检查范围及相关车间、生产线：1.原料药（糠酸莫米松）：806、863车间， A3生产线；2.原料药（倍他米松）：802车间，BETB生产线 检查时间：2025年11月12日-2025年11月14日 检查结论：符合《中华人民共和国药品管理法》《药品生产监督管理办法》 《药品生产质量管理规范》（2010年修订）和相关附录等有关要求。 | 主要生产品 ...

Core Viewpoint - The company received a GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, indicating that its production facilities will be inspected in November 2025, and the results are expected to have no significant impact on performance [1] Group 1: Inspection Details - The inspection will take place from November 12 to 14, 2025, at the company's production site in Tiantai County, Zhejiang, covering workshops 806, 863, and 802, as well as related production lines [1] - The inspection involves the active pharmaceutical ingredients mometasone furoate and betamethasone, with the conclusion indicating compliance with relevant requirements [1] Group 2: Sales Performance - In 2024, the sales revenue for mometasone furoate formulations is projected to be 1.43 billion yuan, while betamethasone formulations are expected to generate 15 million yuan [1] - The company notes that product sales are influenced by multiple factors, leading to inherent uncertainties [1]

Core Viewpoint - Aorite (605116.SH) has received the GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, indicating that its production lines meet GMP standards, which will help maintain product quality and production capacity [1] Group 1: GMP Compliance - The company has passed the GMP compliance inspection for its production lines related to raw materials, specifically mometasone furoate and betamethasone [1] - The inspection covered specific workshops and production lines: Workshop 806 and 863 for mometasone furoate, and Workshop 802 for betamethasone [1] Group 2: Impact on Operations - The successful GMP compliance will support the company's ability to meet market demand for its products [1] - The inspection results are not expected to have a significant impact on the company's financial performance [1]

Core Viewpoint - Aorite (605116.SH) has received the Drug GMP Compliance Inspection Notification from the Zhejiang Provincial Drug Administration, indicating that its production lines meet GMP requirements, which will help maintain product quality and production capacity [1] Group 1: GMP Compliance - The company passed the GMP compliance inspection for its raw materials, specifically Mometasone Furoate and Betamethasone, across designated workshops and production lines [1] - The inspection covered workshops 806, 863, and 802, as well as production lines A3 and BETB [1] Group 2: Impact on Operations - The successful GMP compliance will support the company's ability to meet market demand for its products [1] - The inspection results are not expected to have a significant impact on the company's financial performance [1]